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Summary. The pharmacokinetics of tritiated hexahydro-
sila-difenidol ([3 H]-HHSiD) were examined in rats. Fur-
thermore, the distribution of radioactivity was studied by 
means of whole body autoradiography. 
After i. v. administration of 2.9 mg/kg HHSiD plus 
[3H]-HHSiD to anaesthetized rats bearing a catheter im-
planted in the ductus choledochus and receiving a manni-
tol infusion, HHSiD was rapidly distributed and 
metabolized. Only 5% ofthe radioactivity was recovered 
in blood after 23 s and 0.4% after 2.5 h. 64% of the 
plasma radioactivity could be extracted with hexane from 
the samples taken 23 s after administration. 52% of the 
radioactivity was eliminated within 2.5 h, 13% by urinary 
and 39% by biliary excretion. 
Following oral administration of 8.6 mg/kg HHSiD 
plus [3H]-HHSiD there was an absorption of approxi-
mately one fourth of the administered radioactivity 
within 4 h. By means of whole body autoradiography 
(i. v. injection) as weil as by tissue distribution measure-
ment the highest Ievels of radioactivity were found in bile, 
urine, lung, kidney, adrenals, liver and .pancreas. Thus, 
after i. v. administration to rats HHSiD is rather quickly 
distributed, metabolized and excreted. This explains its 
low antimuscarinic potency in vivo. 
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Introduction 
The antimuscarinic agent hexahydro-sila-difenidol 
(HHSiD, Fig. 1) is used in experimental pharmacology 
to differentiate subtypes of muscarinic receptors (m-
cholinoceptors) due to its selectivity pattern M3 ~ M1 
> M2 (Mutschler and Lambrecht 1984; Fuder et al. 
1985; Lambrecht et al. 1988, 1989; Waelbroeck et al. 
1989). In in-vitro functional experiments as weH as in 
binding sturlies HHSiD and pirenzepine showed a similar 
Send offprint requests to E. Mutschier at the above address 
affinity for muscarinic M1 receptors (Lambrecht et al. 
1988, 1989; Lazareno and Roberts 1989; Waelbroeck et 
al. 1988, 1989). On the other hand, the M1-antimuscarinic 
potency ofHHSiD observed in in-vivo studies with pithed 
rats (antagonism of McN-A-343-induced increase in 
mean arterial pressure) after i. v. administration (Lam-
brecht et al. 1984; Lambrecht and Mutschier 1985) was 
1.5 orders of magnitude lower than that of pirenzepine. 
A different pharmacokinetic behaviour of the two drugs 
may be responsible for this discrepancy. 
Besides this, very littleis known about the pharmaco-
kinetics of organosilicon compounds and basic informa-
tion referring to this is lacking (Tacke and Linoh 1989). 
It was the aim of this study to investigate the 
pharmacokinetics ofHHSiD in rats. Our interest concen-
trated on a determination of plasma Ievels, tissue distri-
bution and elimination pathways of [3H]-HHSiD and its 
metabolites after i. v. administration. 
Although it was not possible to differentiate between 
HHSiD and its metabolites because total radioactivity 
was measured, pharmacokinetic parameters were calcu-
lated from these data. They might therefore be regarded 
as purely experimental quantities. 
An abstract of this work has been presented pre-
viously to the Mainz spring meeting of the German So-
ciety ofPharmacology and Toxicology, March 1988 (Ret-
tenmayr et al. 1988). 
Materials and methods 
Materials. [3H]-Hexahydro-sila-difenidol ([3H]-HHSiD; 12.8 
x 1014 Bq/mol, 98% radiochemical purity) was synthesized in Co-
operation with NEN (Boston, USA). The drug was Iahelied with 
tritium in the piperidino ring. HHSiD hydrochloride (all quantities 
refer to the hydrochloride) was synthesized according to the Iitera-
ture (Tacke et al. 1985). The other chemieals were of reagent grade 
and were used as purchased . 
Autoradiographie studies. The distribution of radioactivity in male 
Wistar rats (body weight approximately 200 g) was studied by means 
of the whole body autoradiography methods of Ullberg (1954, 
1958) and van der Kleijn (1969). 
Fig. 1. Chemical structure of hexahydro-sila-difenidol (HHSiD) 
Rat 1: 26 min after injection of about 7.4 x 106 Bq [3H]-HHSiD 
(corresponding to 1.9 J.Lg) in 0.5 ml of Tyrode solution into the tail 
vein, the rat was anaesthetized with 60 mg/kg of pentobarbitone 
sodium i. p., shaved and fixed on a specially developed device in 
stretched position. Thirty-five minutes after i. v. injection, the rat 
was sacrificed and simultaneously stiffened by submersion in iso-
pentane cooled with solid carbon dioxide (- 80°C). Tail and legs 
were removed and the body was embedded in carboxymethyl cellu-
lose gel (5%). Sagittal sections of 30 J.LID thickness were made with 
a microtome (LKB 2250-PMV, MV, Stockholm, Sweden) in a re-
frigerated room (temperature approximately -15° C). After fixing 
the sections on scotch tape (Permanent Mending Tape No. 810, 3M 
Co., USA), the tissue was freeze-dried, pressed onto Kodak X-
OMAT AR films and exposed for 15 weeks at a temperature be-
low -10°C. 
Basedon the results of this pilot experiment (rat 1) a few changes 
of the experimental design were made to determine the tissue distri-
bution in more detail. For example, in rat 1 most ofthe radioactivity 
was found in the urinary bladder andin the small intestine (excretion 
with the bile). Thus, the time between application of radioactivity 
and death of the animal was shortened in rat 2. 
Rat 2: A mixture of 1.8 x 107 Bq [3 H]-HHSiD (corresponding to 
4.8 J.Lg) and 0.55 mg of unlabelled HHSiD in 0.5 ml of physiological 
salt solution (0.9% NaCl, wfv) was injected i. v. Three minutes later 
the rat was anaesthetized with halothane, fixed in the stretched 
position and killed 4.5 min after administration as described above. 
In order to reduce electrostatic charge when removing the film 
after the exposure time of 6 weeks, rat 2 was embedded in a more 
concentrated carboxymethyl cellulose gel (8%). All other conditions 
were tbe same as described by Ullberg (1954, 1958) and van der 
Kleijn (1969). 
Pharmacokinetic studies. i. v. administration . Male Wistar rats of 
about 300 g (n = 4) were anaesthetized with pentobarbitone sodium 
(60 mg/kg, i. p.). The trachea was intubated and the animals were 
artificially respirated (N20/02 = 1: 1). The jugular vein was cannula-
ted with a polyethylene cannula and a 5% mannitol solution (4 ml/ 
h) was administered in order to obtain a constant urine flow. A 
small amount ofpentobarbitone sodium (22 mg/kg/h) was added to 
the infusion solution for maintenance of anaesthesia. Blood pressure 
was measured via a cannula placed in the carotid artery. The abdo-
men was opened and the bile duct and the urinary bladder were 
cannulated (for details see Mulder et al. 1981). Finally, the femoral 
artery was catheterized for rapid blood sampling. During the exper-
imentnormal body temperature (37.5-38.5°C) was maintained by 
placing the animal on a heating pad (the temperature was monitored 
rectally). [3H]-HHSiD was given as an i. v. bolus injection via the 
femoral vein 30 min afterfinishing the operation. In order to obtain 
a therapeutically relevant dose, tritiated HHSiD was diluted with 
unlabelled HHSiD [approximately 2.2 x 106 Bq, corresponding to 
0.6 J.Lg plus 0.9 mg unlabelled HHSiD in 0.5 ml of physiological 
salt solution (0.9% NaCl, wfv)] and administered to each of four 
anaesthetized rats. 
Immediately after injection of HHSiD together with 3H-HHSiD 
blood, bile and urine samples were collected in polypropylene tubes 
at varying intervals. The samples from the first two rats had been 
collected in untreated vials. Because the results were found to be 
influenced by adsorption ofHHSiD to the walls ofthe blood vials all 
vials used for rat 3 and 4 were siliconized (Silicon, Roth, Karlsruhe, 
FRG). There was no drug adsorption onto vial walls from bile and 
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urine samples. Therefore, under Results plasma concentrations only 
of rat 3 and 4 are presented. The blood vials were heparinized 
(each via! contained 2 globules impregnated with Li-heparin from a 
Monovette, Sarstedt, Eindhoven, The Netherlands). Plasma 
samples were prepared immediately after every blood collection by 
centrifugation (2000 x g, 10 min). After drawing the last sample 
2.5 h after administration the rats were killed by an overdose of 
pentobarbitone sodium and samples of different tissues (25-
200 mg) were taken. The skin was removed and the rest of the body 
homogenized. Sampies were taken from the homogenized rat and 
from different sections of the skin. 
Processing of samples. To 10 or 25 J.d aliquots of plasma, urine or 
bile 10 ml ofscintillation fluid (Aqualuma, Lumac, Schaesberg, The 
Netherlands) were added and radioactivity was determined. 
In order to separate the parent drug and lipophilic metabolites 
from more hydrophilic metabolites, aliquots of the various samples 
were extracted with n-hexane and radioactivity was determined in 
the n-hexane extract. Forthis purpese 10 or 25 J.Ll aliquots of plasma, 
urine or bile of two rats were diluted with water to a volume of 
100 J.Ll in siliconized Eppendorf vials. The samples were alkalized by 
addition of 20 J.Ll of 0.1 molfl NaOH and extracted three times with 
aliquotsoft ml ofn-hexane(centrifugation for 10 min at 18000 x g). 
The three n-hexane extracts of each sample were pooled and the 
organic solvent was allowed to evaporate. Radioactivity was rnea-
sured in 10 ml Aqualuma. In some preliminary experiments it was 
found that at least 97% of HHSiD, along with hexane soluble 
metabolites, is extracted with this method. 
The skin samples and the other homogenized tissue samples 
were dissolved in Soluene 100 (Packard, Groningen, The 
Netherlands) at 60°C and radioactivity was determined after ad-
dition of 15 ml of a mixture of Insta-Gel (Packard) and 0.5 molfl 
HCl (9: 1. vfv). 
The radioactivity was measured in a liquid scintillation counter 
(Packard). The queuehing was corrected by external standardiza-
tion. 
Oral administration. In order to determine the absorbed fraction of 
HHSiD afteroral administration, a dose of [3H]-HHSiD was given 
to one rat (body-weight: 282 g) after withdrawal of food for 24 h. 
A mixture of 6.3 x 106 Bq [3H]-HHSiD (corresponding to 1.7 J.Lg) 
plus 2.42 mg of unlabelled HHSiD (8.6 mg/kg) in 1.2 ml of water 
was injected into the stomach. The experimental design was the 
same as in the i. v. experiments except the duration of sampling ( 4 h). 
At the end of the experiment the skin was temoved. Stomach 
and intestine were taken from the body and homogenized. The rest 
of the body was also homogenized and samples were taken for 
measurement of radioactivity. 
Pharmacokinetic calculations. Plasma concentration and excretion 
rate data were fitted to the usua!'multiexponential equations using 
the NONLIN computerprogram (Metzler et al. 1974). Data were 
weighted reciprocally. Using standard methods basic pharmaco-
kinetic parameterssuch as distribution half-life (t 112 Dis), elimination 
half-life (t 112 EJ), half-lives of urinary and biliary excretion rate 
(t112 u, t 112 Bit), plasma clearances (CL) and mean residences time 
(MRT) were calculated from these fits (Gibaldi and Perrier 1982). 
The biliary and renal clearances (CL8 iJ, CLR) were determined by 
D811 , u · CL/1 00. The percentage of dose excreted with urine and bile 
extrapolated to infinity (Du, D8 it) %D was calculated by the area 
under the excretion rate curve AUCo-co · 100/D. Time ofmaximum 
excretion rate ofbile and urine {tmaxB• tmaxu) were obtained from the 
curves. 
Results 
Whole body autoradiography 
In the animal that was sacrificed after 4.5 min (rat 2; 
Fig. 2), the radioactivity bad already spread over the 
whole body. The highest concentration of radioactivity 
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Fig. 2. Autoradiograms of two different sagittal sections of one rat, showing the distribution of radioactivity 4.5 min after i. v. injection of 
1.8 x 107 Bq [3H]-HHSiD plus 0.55 mg HHSiD. White areas in the autoradiograms indicate the presence ofradioactivity 
was found in the lung. High concentrations could also be 
observed in the kidney, urine and gastric mucosa. A less 
pronounced accumulation of radioactivity was found in 
the adrenals, liver (the liver showed a spotted pattern), 
brain, muscle, intestinal walls, heart andin the glandular 
tissues, such as pancreas and salivary gland. On the other 
hand, the autoradiograms showed no radioactivity in the 
blood. 
After 35 min (rat 1; Fig. 3) extremely high concen-
trations of radioactivity could be observed in the urinary 
bladder, the duodenum and on the skin. The liver still, 
and more clearly, showed a spotted pattern, whereas the 
radioactivity of the stomach had shifted slightly further 
away from the mucosa. Only low concentrations were 
detectable in kidney, pancreas and lung. The rest of the 
body showed hardly any radioactivity. 
/. v. administration to anaesthetized rats 
Plasma radioactivity. The plasma concentrations present-
ed are the mean values of data obtained from two rats 
(No. 3 and 4). Figure 4 shows the data from a single 
experiment. 
The radioactivity remaining in the plasma 23 s after 
i. v. administration ofHHSiD together with [3H]-HHSiD 
represented only 5% ofthe theoretical value at time zero 
(plasma volume was assumed to be 7.5 ml). The radioac-
tivity decreased to 1% of the calculated initial value 
within the first 10 min and to 0.4% within 2.5 h. The 
estimated terminal half-life was 3.3 h. 64% ofthe plasma 
radioactivity could be extracted with hexane from the 
samples drawn 23 s after administration. This percentage 
decreased to 11% after 2.5 h. Half-life of the plasma 
radioactivity was 1.4 h in case of the extracts. 
Urinary excretion. A measurable urinary excretion 
(Fig. 5) of radioactivity started within 3 min after the i. v. 
dose (n = 4). The maximum excretion rate was reached 
after 12.5 min with a 95-fold higher ooncentration in urine 
than in plasma at the same time. The radioactivity ex-
tracted with hexane ranged from 46% in the beginning 
(total radioactivity of the respective sample expressed as 
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Fig. 3. Autoradiogram showing the distribution of radioactivity 35 min after i. v. administration of7.5 x 106 Bq [3H]-HHSiD to a rat 
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Fig. 4. Plasma radioactivity after i. v. injection of 2.2 x 106 Bq [3H]-
HHSiD plus 3 mg/kg HHSiD in rat No. 3 [total activity (e) and 
radioactivity (HHSiD and its lipophilic metabolites) extracted with 
hexane (0)] 
100%) to 13% at the end. The maximum excretion rate 
ofhexane-soluble radioactivity was observed 20 min after 
administration. The calculated half-lives were 1.4 h (total 
activity) and 1.7 h (radioactivity extracted with hexane). 
Biliary excretion. Radioactivity was detectable in bile 
(Fig. 6) already in the first minute after i. v. administra-
tion (n = 4). The maximum excretion rate was reached 
after 6 min with a 360-fold higher concentration in bile 
than in plasma at the same time. The concentration of 
radioactivity in bile was higher than in any other tissue 
or body fluid. During the period of 9 min to 2.5 h after 
i. v. administration ofthe drug, the radioactivity extracted 
from bile with hexane accounted for about 1 -2% of the 
total activity of the respective sample. Half-lives from 
excretion rates were 1.6 h (total activity) and 0.8 ·h (radio-
activity extracted with hexane). 
Total excretion. 52% ofthe i. v. administered radioactivity 
was excreted within 2.5 h, excretion in urine and bile 
arriounting to 13% and 39%, respectively. Extrapolation 
to infinity resulted in a total recovery of 17% in urine 
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Fig. 5. Urinary excretion rates (upper panel) and cumulative urinary 
excretion (lower panel) of radioactivity after i. v. injection of 
2.2 x 106 Bq [3 H]-HHSiD plus 3 mg/kg HHSiD in rat No. 3 [total 
activity ( e) and radioactivity (HHSiD and its lipophilic metab-
olites) extracted with bexane (0)] 
and 52% in bile. The radioactivity extracted with hexane 
was 2.9% of the dose (4.2o/o after extrapolation) in case 
ofurine and 0.7% (0.7 after extrapolation) in case ofbile. 
Distribution ofradioactivity. At the end ofthe experiments 
(2.5 h after i. v. administration) 47.3% of the dose could 
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Fig. 6. Biliary excretion rate (upper panel) and cumulative biliary 
excretion (lower panel) of radioactivity after i. v injection of 
2.2 x 106 Bq [3H]-HHSiD plus 3 mg/kg HHSiD in rat No. 3 [total 
activity (e) and radioactivity (HHSiD and its lipophilic metab-
olites) extracted with hexane (0)] 
still be detected in the animals. At that time drug levels 
in all tissues were higher than the corresponding plasma 
concentrations. High levels of radioactivity were found 
in bile, urine, pancreas, lung, spleen, liver, adrenal and 
kidney (Fig. 7). 
Pharmacokinetic parameters. From the plasma concen-
tration time curves and the urine and bile excretion curves 
pharmacokinetic parameters were calculated. These data 
are summarized in Table 1. 
Oral administration 
Plasma concentration. Thirty minutes after oral 
administration plasma radioactivity reached a plateau 
until the end of the experiment (4 h, Fig. 8). The highest 
yield ofradioactivity extracted with hexanewas observed 
after 12 min. The extracted fraction ranged from 15% of 
the total activity in the beginning to 1.5°/o at the end. 
Distribution of radioactivity. At the end of the experiment 
( 4 h after oral administration) the radioactivity was dis-
tributed as follows: Skin 1.1 %, starnach and intestine 
0 2 8 
Mean value 
~Tissue 
Deviation 
10 12 14 
Fig. 7. Tissue distribution ofradioactivity 2.5 h after i. v. administra-
tion of [3 H]-HHSiD plus 3 mg/kg HHSiD [values of three rats 
(Bq/g) relative to the average total radioactivity of the respective 
homogenized rat (Bq/g) which was arbitrarily set as 1]. Shadedparts 
of colurnns are maximum deviations from sample mean 
73.5%, rest of the body 9.3%, excreted via urine 2.9%, 
excreted via bile 13.1% (sum = 99.9%). 
Total excretion. Four hours after oral administration 
16% of the administered radioactivity had been excreted 
(2.9% via urine and 13.1% via bile). Extrapolation to 
infinity resulted in a recovery of 2.9% in urine and 15°/o 
in bile. The fraction of radioactivity ~xtracted with hex-
ane was 0.11% of the dose (0.11% after extrapolation) 
in case of urine and 0.16% (0.17% after extrapolation) 
in case of bile. 
Discussion 
After i. v. injection of [3H]-HHSiD tagether with 
unlabelled HHSiD, the rate of drug disappearance from 
plasma is particularly striking: 95% of the administered 
radioactivity disappeared from plasma within 23 s and 
99% within 10 min. Due to this rapid distribution no 
radioactivity could be seen in the blood of the 
autoradiograms taken 4.5 min after the injection (Fig. 2), 
although radioactivity was detectable in most tissues. The 
presenee of tritium in the brain shows that HHSiD can 
pass the blood brain barrier. An extremely high tritium 
concentration was detected in the Jungafter 4.5 min. 
In the autoradiograms taken 35 min after i. v. 
administration (Fig. 3), very high concentrations of 
tritium in the urinary bladder and the duodenum indicate 
a rather quick and effective urinary and biliary elimin-
ation. 
The radioactivity noticed on the skin is probably the 
result of a contamination with urine. The spotted pattern 
of activity distribution in the liver is caused by the in-
tralobular concentration of radioactivity in the bile. 
Twenty-three seconds after i. v. administration only 
64% of the total radioactivity in plasma could be extrac-
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Table 1. Pharmacokinetic parameters obtained after i.v. administration of [3 H]-HHSiD plus unlabelled HHSiD with total and hexane-
extractable (in brackets) radioactivity. For explanation of terms see Methods 
Rat No. 1 
Weight (g) 315 
Dose [3H]-HHSiD (Bq x 106) 1.87 
Dose HHSiD (mg) 0.73 
CL (mljmin) 
CLnu (ml/min) 
CLR (ml/min) 
Du (%) 19.6 
DBil (%) 62.5 
tl / 2EI (h) 
tl /2Dis (s) 
(1 / 2Bil (h) 2.2 
l 1/2U (h) 1.6 
lmaxB (min) 7 
lmaxU (min) 22 
MRT (min) 
* Measured maximum was taken 
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Fig. 8. Plama concentration-time curve after oral administration of 
6.3 x 106 Bq [3H]-HHSiD plus 8.6 mg/kg HHSiD [total activity (e) 
and radioactivity (HHSiD and its lipophilic metabolites) extracted 
with hexane (0)] 
ted with hexane, thus indicating that already at that time 
36% of the radioactivity in plasma is due to hydrophilic 
metabolites no Ionger extractable with hexane. By 
analogy to the metabolism ofthecarbon compound hexa-
hydro-difenidol (Tacke and Linoh 1989), the main meta-
bolic pathway ofthe silicon analogue HHSiD is the intro-
duction of one, two or three hydroxy groups preferably 
located at the cyclohexyl ring but also at the phenyl 
moiety (Rettenmayr et al. 1988; Strohmann et al. 1988). 
After i. v. administration the radioactivity extracted from 
plasma with hexane is ranging from 64% in the beginning 
to 11% at the end, and in case of oral administration 
from 12% to 2%, respectively. These data can best be 
explained by a first pass metabolism. 
Incubation of blood with [3H]-HHSiD and determi-
nation of radioactivity in plasma and centrifuged blood 
cells showed that the amount of radioactivity was about 
the samein both fractions (46% in plasma and 54% in 
centrifuged blood cells) (unpublished observations). 
3 
300 
2.17 
0.90 
7.7 (47.6) 
3.4 (0.4) 
1.4 (2.2) 
17.9 (4.6) 
44.7 (0.8) 
3.2 {1.5) 
38.8 (37.0) 
1.0 (0.8) 
1.2 (2.0) 
8 (2) 
21 (20) 
262 (90) 
4 
304 
2.37 
0.98 
5.7 (46.5) 
3.0 (0.3) 
1.0 (1.7) 
17.9 (3.7) 
52.6 (0.6) 
3.4 (1.3) 
17.3 (20.5) 
1.5 (0.9) 
1.1 (1.4) 
6* (2) 
20 (18) 
279 (72) 
I t appears from Table 1, where biliary and renal clear-
ances tagether (hexane extract) are much lower than 
plasma clearance, that there must be another elimination 
route, probably the metabolic clearance . 
It is interesting to note that there is a good correlation 
between the pharmacokinetic results (course of the con-
centration-time curve of HHSiD extracted from plasma, 
Fig. 4) and the course of the pharmacodynamic effects 
on the eye after oral administration of 5 mgfkg HHSiD 
to mice. The dilatating effect on the pupil was reported 
to be quite strong in the beginning and to decrease rapidly 
during the first hour (JI. Kromer and U. Brand, Byk 
Gulden, Konstanz, FRG, unpublished results). Com-
pared to HHSiD the carbon analogue hexahydro-di-
fenidol showed a Ionger duration of mydriatic effect. A 
similar experiment using procyclidine and sila-pro-
cyclidine showed that the silicon analogue exhibited a 
Ionger duration ofpupillary dilatation (Tacke et al. 1987). 
The main fraction of [3H]-HHSiD radioactivity is 
concentrated in liver and excreted via bile as can be seen 
in the total excretion ofradioactivity (see Results), which 
was 52% of the administered dose in case of the bile. 
The high amount oftritium found in the stomach and 
intestine (the bile was collected) afteroral administration 
(74% ofthe administered dose; 4 h after administration; 
see Results) indicates a poor absorption of HHSiD. A 
direct excretion into the intestine cannot play an import-
ant role, as faeces and the contents of the small intestine 
contain only a small amount of radioactivity after i. v. 
administration to anaesthetized rats with a cannulated 
bile duct (data not shown). 
In conclusion, the results of this study provide strong 
evidence that pharmacokinetic reasons (the quick 
metabolization and the fast excretion) are responsible 
for the reported differences between the in vivo M1-
antimuscarinic activities (lower potency of HHSiD com-
pared to pirenzepine in the pithed rat, see Introduction) 
and the in vitro M1-binding affinities (HHSiD similar to 
pirenzepine ). 
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